Literature DB >> 8286207

Pretreatment serum CRP and response to interleukin 2.

J Y Blay, S Négrier, T Philip, M Favrot, A Mercatello.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8286207      PMCID： PMC1968782          DOI： 10.1038/bjc.1994.35

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  5 in total

1.  Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.

Authors:  J Y Blay; S Negrier; V Combaret; S Attali; E Goillot; Y Merrouche; A Mercatello; A Ravault; J M Tourani; J F Moskovtchenko
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

2.  Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects.

Authors:  L G Thijs; C E Hack; R J Strack van Schijndel; J H Nuijens; G J Wolbink; A J Eerenberg-Belmer; H Van der Vall; J Wagstaff
Journal:  J Immunol       Date:  1990-03-15       Impact factor: 5.422

3.  Anti-C-reactive protein inhibits the calcium-dependent stage of natural killer cell activation.

Authors:  W H Hamoudi; L L Baum
Journal:  J Immunol       Date:  1991-04-15       Impact factor: 5.422

4.  Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes.

Authors:  G Vachino; J A Gelfand; M B Atkins; J D Tamerius; P Demchak; J W Mier
Journal:  Blood       Date:  1991-11-15       Impact factor: 22.113

5.  Interleukin 2 therapy in cancer: identification of responders.

Authors:  J Broom; S D Heys; P H Whiting; K G Park; A Strachan; I Rothnie; C R Franks; O Eremin
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640
  5 in total
  4 in total

Review 1.  C-reactive protein as a biomarker for urological cancers.

Authors:  Kazutaka Saito; Kazunori Kihara
Journal:  Nat Rev Urol       Date:  2011-10-25       Impact factor: 14.432

2.  Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer.

Authors:  W G Simpson; S D Heys; P H Whiting; O Eremin; J Broom
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

3.  Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines.

Authors:  R E Banks; M A Forbes; S Hallam; A Jenkins; M Wadhwa; P Dilger; A Meager; R Thorpe; C J Bowmer; J K Joffe; P Patel; P W Johnson; P J Selby
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 4.  COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?

Authors:  Antonio Macciò; Sara Oppi; Clelia Madeddu
Journal:  J Ovarian Res       Date:  2021-02-08       Impact factor: 4.234
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.